www.fdanews.com/articles/202607-biovaxys-bioelpida-collaborate-to-produce-ovarian-cancer-vaccine
BioVaxys, BioElpida Collaborate to Produce Ovarian Cancer Vaccine
May 4, 2021
Vancouver, Canada-based BioVaxys Technology has struck a deal with BioElpida for production and aseptic packaging of BioVaxys’ ovarian cancer vaccine candidate, BXV-0918A, at its facility in Lyon, France.
BioVaxys is developing BVX-0918A with Spanish drugmaker ProCare Health Iberia, which expects to apply to the European Medicines Agency for compassionate use authorization later this year for stage 3/stage 4 ovarian cancer.
BioVaxys is also developing vaccines against ovarian cancer and the SARS-CoV-2 virus.